Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as cellular adoptive immunotherapy use different ways to
stimulate the immune system and stop cancer cells from growing. Fludarabine may help the
immune system kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of fludarabine followed by cellular
adoptive immunotherapy in treating patients who have metastatic melanoma.